Results 101 to 110 of about 32,319 (241)

Adverse Reactions Identified after Approval of Novel Medicines: Analysis of 339 New Molecular Entities and Therapeutic Biologics

Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 1120-1128, October 2026.
Postmarketing safety surveillance data identify safety issues not identified in preapproval clinical trials. We describe the frequency of new safety issues overall and by labeling section and the relationship of the most commonly added safety issues with the cumulative number of prescriptions dispensed via retail pharmacies.
Ellen Pinnow, Brendan Day, Esther H. Zhou, Corinne Woods, Nana Dwumfour, Jenni Y. Lee, Ilynn Bulatao, Sanae Cherkaoui, Manish Kalaria, Sonja Brajovic, Nabila Sadiq, Farideh Sistani, Maggie Lee, Grace Chai, Gerald Dal Pan   +14 more
wiley   +1 more source

Leukoencephalopathy in patients with ischemic stroke.

, 1987
Thirty-one (16 women, 15 men; mean age 68 years) of 1,000 consecutive patients with an ischemic stroke investigated systematically with computed tomography (CT), Doppler, electrocardiography (ECG), and biological tests had a diffuse hypodensity of the ...
A Uske, F Regli, J Bogousslavsky
core   +1 more source

Cross‐Neutralizing and Broadly Neutralizing Human Antibodies Against Nonenveloped Viruses

European Journal of Immunology, Volume 56, Issue 10, October 2026.
In this review article, Marchand et al. compare cross ‐ and broadly ‐neutralizing human antibodies against non ‐ enveloped viruses from several major families, discussing their structural characteristics, neutralization mechanisms and relevance for the development of antiviral vaccines and therapeutics.
Sarah Marchand, Samy Taouli, Dorian McIlroy   +2 more
wiley   +1 more source

Cell Type‐Specific Extracellular Vesicles in Mouse Brain: Proteomic Signatures Highlight Astrocytic GlialCAM Network and GPCR Enrichment

Glia, Volume 74, Issue 10, October 2026.
Cell type–specific EVs were isolated from mouse brain and profiled by proteomics. Each EV subtype exhibited proteomic signatures consistent with the specialized functions of its cell of origin. Astrocyte‐derived EVs (ADEVs) were enriched for the GlialCAM/MLC1 network and GPCRs.
Alba M. Lucart‐Sanchez, Edward Sellés‐Climent, Jorge Navarro‐Calvo, Guillem Pont‐Espinós, Jose A. Gomez‐Sanchez, Raúl Estévez, Luis M. Valor, Rocío Pérez‐González   +7 more
wiley   +1 more source

Brain Atrophy and Leukoencephalopathy Following Tarlatamab: Case Report

Respirology Case Reports
We describe the case of a 74‐year‐old female diagnosed with extensive‐stage small cell lung cancer. Initially, she received carboplatin, etoposide and atezolizumab, followed by amrubicin as second‐line treatment and nogitecan as third‐line treatment ...
Kiriko Onishi, Toki Kitano, Yusuke Fujioka, Moeko Ota, Fumie Onishi, Kohei Miyake, Hisaaki Tanaka, Nobukazu Fujimoto   +7 more
doaj   +1 more source

Progressive Multifocal Leukoencephalopathy or Lymphoma? A Massive Unilateral Hemispheric Mimicker in a Patient Undergoing Lymphoma Treatment

Reports
An 81-year-old woman with follicular lymphoma treated with obinutuzumab and bendamustine developed cognitive impairment and dysarthria. Three months before death, neurological exams showed dysarthria, right hemiparesis, and gait disturbance.
Koji Hayashi, Mamiko Sato, Hiroki Tsukamoto, Eiju Negoro, Takahiro Yamauchi   +4 more
doaj   +1 more source

One cycle of nelarabine given after induction is well tolerated but does not improve outcome in adults with T‐cell precursor acute lymphoblastic leukemia: Outcome data from the UKALL14 randomized‐controlled trial

HemaSphere, Volume 10, Issue 10, October 2026.
Abstract UKALL14 (NCT01085617) T‐cell arm was a phase 3, randomized‐controlled trial. Adults aged 25–65 years were randomized 1:1 at entry to receive standard of care (SOC) or SOC + nelarabine 1.5 g/m2 (Days 1, 3, and 5) to be administered following second induction. The primary end‐point was event‐free survival (EFS).
Clare J. Rowntree, Amy A. Kirkwood, Nadine Farah, Emma Lawrie, David I. Marks, Andrew K. McMillan, Tobias F. Menne, Anthony V. Moorman, Bela Patel, Pip Patrick, Paul Smith, Krisztina Z. Alapi, Lingyi Wang, Marc R. Mansour, Adele K. Fielding   +14 more
wiley   +1 more source

Harnessing Natural Killer Cells: From Neuroimmunology to Novel Therapies for Central Nervous System Diseases

MedComm, Volume 7, Issue 10, October 2026.
This review delineates the multifaceted roles of natural killer (NK) cells in the central nervous system, spanning direct cytolysis, immunoregulation, and crosstalk with the brain microenvironment. We evaluate the translational potential and challenges of NK cell immunotherapies for a spectrum of neurological conditions.
Kaihang Deng, Wai Po Chong
wiley   +1 more source

Posterior fossa tremor induced by HIV-associated progressive multifocal leukoencephalopathy [PDF]

, 2005
Sporer, B., B. Sporer, K. Seelos, H.-W. Pfister, F. Asmus, Seelos, Klaus, Bötzel, Kai, K. Boetzel, Asmus, F., Pfister, H. W.   +9 more
core   +1 more source

Remission of progressive multifocal leukoencephalopathy following highly active antiretroviral therapy in a man with AIDS

, 2012
Katie Yoganathan1, David Brown2, Kathir Yoganathan31Cardiff Medical School, Cardiff, Wales, UK; 2Virus Reference Department, Microbiology Services, Health Protection Agency, London, UK; 3Singleton Hospital, Abertawe Bro Morgannwg University Health Board,
Yoganathan K, Brown D
core